Limits...
Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke

View Article: PubMed Central - PubMed

ABSTRACT

Objective:: This study aims to observe the clinical efficacies of hyper-early low-dose alteplase thrombolysis in treating acute ischemic stroke (AIS).

Methods:: Two hundred twenty AIS patients were randomly divided into group A (90 cases), group B (90 cases), and group C (40 cases). The National Institutes of Health Stroke Scale (NIHSS) scores, mRS score-evaluated prognosis, intracranial hemorrhage, and mortality of the three groups were observed before and after the treatment.

Results:: The NIHSS scores of the three groups were significantly reduced after the treatment (P<0.05), among which the NIHSS score of group A was the lowest (P<0.05); and the difference between group B and C was not significant (P>0.05). The incidence of such complications as cerebral hemorrhage in the three groups was low, and there was no significant difference among the groups (P>0.05). The modified Rankin Scale (mRS)scores of the three groups showed that group A had much better prognosis than group B and C, while the difference between group B and group C was not significant.

Conclusions:: The hyper-early low-dose alteplase thrombolysis was safe and effective in Acute ischemic stroke (AIS).

No MeSH data available.


Related in: MedlinePlus

Rates of good prognosis of the three groups 90 days after the treatment; &compared with group B after the treatment, P<0.05; #compared with group C after the treatment, P<0.05
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5017082&req=5

Figure 2: Rates of good prognosis of the three groups 90 days after the treatment; &compared with group B after the treatment, P<0.05; #compared with group C after the treatment, P<0.05

Mentions: The mRS scores of the three groups 90 days after the treatment showed that group A had 65 cases evaluated as good prognosis, group B had 49 cases, and group C had 22 cases (Fig.2). The prognosis of group A was significantly better than group B and C, and the intergroup differences were significant (PAB=0.015, PAC=0.034); however, the difference between group B and C was not significant (PBC=0.889).


Clinical efficacy and safety of hypernormal shortened door to needle time (DNT) plus individualized low-dose alteplase therapy in treating acute ischemic stroke
Rates of good prognosis of the three groups 90 days after the treatment; &compared with group B after the treatment, P<0.05; #compared with group C after the treatment, P<0.05
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5017082&req=5

Figure 2: Rates of good prognosis of the three groups 90 days after the treatment; &compared with group B after the treatment, P<0.05; #compared with group C after the treatment, P<0.05
Mentions: The mRS scores of the three groups 90 days after the treatment showed that group A had 65 cases evaluated as good prognosis, group B had 49 cases, and group C had 22 cases (Fig.2). The prognosis of group A was significantly better than group B and C, and the intergroup differences were significant (PAB=0.015, PAC=0.034); however, the difference between group B and C was not significant (PBC=0.889).

View Article: PubMed Central - PubMed

ABSTRACT

Objective:: This study aims to observe the clinical efficacies of hyper-early low-dose alteplase thrombolysis in treating acute ischemic stroke (AIS).

Methods:: Two hundred twenty AIS patients were randomly divided into group A (90 cases), group B (90 cases), and group C (40 cases). The National Institutes of Health Stroke Scale (NIHSS) scores, mRS score-evaluated prognosis, intracranial hemorrhage, and mortality of the three groups were observed before and after the treatment.

Results:: The NIHSS scores of the three groups were significantly reduced after the treatment (P&lt;0.05), among which the NIHSS score of group A was the lowest (P&lt;0.05); and the difference between group B and C was not significant (P&gt;0.05). The incidence of such complications as cerebral hemorrhage in the three groups was low, and there was no significant difference among the groups (P&gt;0.05). The modified Rankin Scale (mRS)scores of the three groups showed that group A had much better prognosis than group B and C, while the difference between group B and group C was not significant.

Conclusions:: The hyper-early low-dose alteplase thrombolysis was safe and effective in Acute ischemic stroke (AIS).

No MeSH data available.


Related in: MedlinePlus